BCL6 and neoplasm: To this end, we transplanted LLC-OVA tumor cells into Bcl6-deficient OT-1 or wild-type OT-1 (CD45.2) mice, and then 7 days later sorted tumor-infiltrating CD62L+ OT-1 T cells (Fig 4A and 4B).